Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Relationship between Platelet PPARs, cAMP Levels, and P-Selectin Expression: Antiplatelet Activity of Natural Products.

Fuentes E, Palomo I.

Evid Based Complement Alternat Med. 2013;2013:861786. doi: 10.1155/2013/861786. Epub 2013 Nov 13. Review.

2.

Mechanism of the anti-platelet effect of natural bioactive compounds: role of peroxisome proliferator-activated receptors activation.

Fuentes E, Fuentes F, Palomo I.

Platelets. 2014;25(7):471-9. doi: 10.3109/09537104.2013.849334. Epub 2013 Nov 18. Review.

PMID:
24246093
3.

Mechanism of antiplatelet action of hypolipidemic, antidiabetic and antihypertensive drugs by PPAR activation: PPAR agonists: new antiplatelet agents.

Fuentes E, Palomo I.

Vascul Pharmacol. 2014 Sep;62(3):162-6. doi: 10.1016/j.vph.2014.05.008. Epub 2014 May 27. Review.

PMID:
24874279
4.

Effects of peroxisome proliferator-activated receptor γ in simvastatin antiplatelet activity: influences on cAMP and mitogen-activated protein kinases.

Du H, Hu H, Zheng H, Hao J, Yang J, Cui W.

Thromb Res. 2014 Jul;134(1):111-20. doi: 10.1016/j.thromres.2014.05.005. Epub 2014 May 10.

PMID:
24856644
5.

Regulatory mechanisms of cAMP levels as a multiple target for antiplatelet activity and less bleeding risk.

Fuentes E, Palomo I.

Thromb Res. 2014 Aug;134(2):221-6. doi: 10.1016/j.thromres.2014.04.027. Epub 2014 May 2. Review.

PMID:
24830902
6.

Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.

Gervois P, Fruchart JC, Staels B.

Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):145-56. Review.

PMID:
17237841
7.

Antiplatelet effect of aspirin in patients with coronary artery disease.

Grove EL.

Dan Med J. 2012 Sep;59(9):B4506. Review.

PMID:
22951204
8.

Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors.

Coccheri S.

Drugs. 2010 May 7;70(7):887-908. doi: 10.2165/11536000-000000000-00000. Review.

PMID:
20426498
9.

Platelet activation in atherogenesis associated with low-grade inflammation.

Antoniades C, Bakogiannis C, Tousoulis D, Demosthenous M, Marinou K, Stefanadis C.

Inflamm Allergy Drug Targets. 2010 Dec;9(5):334-45. Review.

PMID:
20632958
10.

Dual Roles of Quercetin in Platelets: Phosphoinositide-3-Kinase and MAP Kinases Inhibition, and cAMP-Dependent Vasodilator-Stimulated Phosphoprotein Stimulation.

Oh WJ, Endale M, Park SC, Cho JY, Rhee MH.

Evid Based Complement Alternat Med. 2012;2012:485262. doi: 10.1155/2012/485262. Epub 2012 Dec 17.

11.

Mechanisms of antiplatelet activity of nifedipine: role of peroxisome proliferator-activated receptor-β-γ-dependent processes.

Shih CY, Lin MH, Fan HC, Chen FC, Chou TC.

J Hypertens. 2014 Jan;32(1):181-92. doi: 10.1097/HJH.0000000000000007.

PMID:
24126710
12.

The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects.

Spinelli SL, O'Brien JJ, Bancos S, Lehmann GM, Springer DL, Blumberg N, Francis CW, Taubman MB, Phipps RP.

PPAR Res. 2008;2008:328172. doi: 10.1155/2008/328172.

13.

Protective mechanisms of adenosine 5'-monophosphate in platelet activation and thrombus formation.

Fuentes E, Badimon L, Caballero J, Padró T, Vilahur G, Alarcón M, Pérez P, Palomo I.

Thromb Haemost. 2014 Mar 3;111(3):491-507. doi: 10.1160/TH13-05-0386. Epub 2013 Dec 5.

PMID:
24306059
14.

Platelets in atherosclerosis.

Lievens D, von Hundelshausen P.

Thromb Haemost. 2011 Nov;106(5):827-38. doi: 10.1160/TH11-08-0592. Epub 2011 Oct 20. Review.

PMID:
22012554
15.

Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients.

Muhlestein JB.

Thromb Haemost. 2010 Jan;103(1):71-82. doi: 10.1160/TH09-03-0177. Epub 2009 Nov 13. Review.

PMID:
20062914
16.

Expression of platelet P-selectin and detection of soluble P-selectin, NPY and RANTES in patients with inflammatory bowel disease.

Fägerstam JP, Whiss PA, Ström M, Andersson RG.

Inflamm Res. 2000 Sep;49(9):466-72.

PMID:
11071121
17.

Peroxisome proliferator-activated receptors and the metabolic syndrome.

Bragt MC, Popeijus HE.

Physiol Behav. 2008 May 23;94(2):187-97. doi: 10.1016/j.physbeh.2007.11.053. Epub 2007 Dec 7. Review.

PMID:
18191967
18.

PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?

Ahmed W, Ziouzenkova O, Brown J, Devchand P, Francis S, Kadakia M, Kanda T, Orasanu G, Sharlach M, Zandbergen F, Plutzky J.

J Intern Med. 2007 Aug;262(2):184-98. Review.

19.
20.

Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin.

Guthikonda S, Lev EI, Patel R, DeLao T, Bergeron AL, Dong JF, Kleiman NS.

J Thromb Haemost. 2007 Mar;5(3):490-6.

Supplemental Content

Support Center